ClinicalTrials.gg
RecruitingNCT06044077Updated Sep 21, 2023

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

A Phase 3 interventional study of 23-valent pneumococcal polysaccharide vaccine and control pneumococcal polysaccharide vaccine in Pneumococcal Disease, sponsored by Aimei Vacin BioPharm (Zhejiang) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,920
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections — 1 open to participants now, 1 under way, 1 of them phase 3. 23-valent pneumococcal capsular polysaccharide vaccine · Pneumococcal Infections.

Planned enrollment
Largest of 15
1,920 · median 243
Started
2023
the only one that year
Phase 3
6 of 15
1 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Among the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, this one has the largest planned enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 15th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections is open now, in 1 country.

By country, each count listing its studies:

About 23-valent pneumococcal capsular polysaccharide vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 2 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects who meet the observation age of this clinical trial (2 years old and above) and are determined based on medical history, physical examination and the researcher's judgment;
  2. Subjects who voluntarily participate and/or the subjects' legal guardians Or the entrusted person voluntarily agrees for his or her child to participate and signs an form (subjects aged 8-17 years old must also sign an informed notification form);
  3. The subject and/or the subject's legal guardian or principal can abide by the clinical Relevant requirements of the research protocol;
  4. *Axillary body temperature \<37.3°C on the day of enrollment. For criteria marked with an asterisk (*), if the subject has the conditions specified in the criterion, the visit can be rescheduled when they no longer have those conditions.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with marketed or experimental pneumococcal vaccines;
  2. Previous culture-confirmed history of invasive diseases caused by pneumococcal bacteria;
  3. History or family history of convulsions, epilepsy, encephalopathy, and mental illness;
  4. Have a history of severe allergy to any vaccination or drug in the past, be allergic to the ingredients of the experimental vaccine (mainly including pneumococcal polysaccharide, sodium dihydrogen phosphate, disodium hydrogen phosphate, and sodium chloride), and have a history of vaccination-related fever (39℃ or above );
  5. Known severe congenital malformations, developmental disabilities or clinically diagnosed serious chronic diseases (such as Down syndrome, diabetes that cannot be controlled by drugs, sickle cell anemia, Guillain-Barré syndrome);
  6. Known or suspected to have serious diseases including: severe respiratory diseases, severe digestive system diseases, severe endocrine system diseases, severe cardiovascular diseases, severe liver and kidney diseases, malignant tumors, severe skin diseases, etc.;
  7. Known or suspected to be immune Academic functional defects include: treatment (radiotherapy, chemotherapy, , antimetabolites, cytotoxic drugs), infection, etc. within 6 months;
  8. Have received any treatment within 3 months before enrollment Blood products or globulin treatment, those who have used immune globulin are acceptable;
  9. Asplenia, functional asplenia or splenectomy;
  10. * In the acute infectious period (including recovery period) or acute exacerbation of chronic disease within 3 days before enrollment, or need or plan to use intravenous or oral steroids within 1 month after vaccination;
  11. * Antipyretic analgesics or anti-allergic drugs have been used within 3 days before enrollment;
  12. Women of childbearing age are pregnant ( Positive urine pregnancy test), breastfeeding or planning to prepare for pregnancy within six months; 13. *Hypertension that cannot be controlled by medication, such as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg in adults aged 18 years and above before enrollment;
  1. * Have received attenuated within 14 days before vaccination, and received inactivated vaccines within 7 days; 15. Are participating in or plan to participate in clinical studies of other drugs or vaccines within 6 months after vaccination (immune persistence observation subjects in the vaccine who plan to vaccinate any marketed or unmarketed pneumococcal vaccine within 6 years after vaccination need to be excluded); 16. The investigators evaluate that they are not suitable for participating in the study.

For criteria marked with an asterisk (*), if the subject has the conditions specified in the criterion, the visit can be rescheduled when they no longer have those conditions.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,920 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    1 dose vaccination of study vaccine

    Biological: 23-valent pneumococcal polysaccharide vaccine

  • Other
    Control Group

    1 dose vaccination of control vaccine

    Biological: control pneumococcal polysaccharide vaccine

Interventions

  • 23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

  • Biologicalcontrol pneumococcal polysaccharide vaccine

    23-valent pneumococcal polysaccharide vaccine from Merck Sharp \& Dohme Corp

06

What researchers measure

Primary outcomes

  1. 2-fold growth rate of IgG antibodies to 23 pneumococcal serotypes on 30 days after vaccination,

    2-fold growth rate of IgG antibodies to 23 pneumococcal serotypes on 30 days after vaccination,

    Time frame: 30 days

  2. Geometric mean concentration (GMC) of IgG antibodies to 23 pneumococcal serotypes on 30 days after vaccination

    Geometric mean concentration (GMC) of IgG antibodies to 23 pneumococcal serotypes on 30 days after vaccination

    Time frame: 30 days

  3. Incidence of adverse reactions/events within 30 minutes of vaccination

    Incidence of adverse reactions/events within 30 minutes of vaccination

    Time frame: 30 min after vaccination

  4. Incidence of adverse reactions/events on days 0 to 7 after vaccination

    Incidence of adverse reactions/events on days 0 to 7 after vaccination

    Time frame: 7 days

  5. Incidence of adverse reaction/event on days 0 to 30 after vaccination

    Incidence of adverse reaction/event on days 0 to 30 after vaccination

    Time frame: 30 days

  6. Incidence of serious adverse events (SAE) within 6 months after vaccination

    Incidence of serious adverse events (SAE) within 6 months after vaccination

    Time frame: 6 months

Secondary outcomes

  1. Geometric mean fold increase (GMFI) of IgG antibodies against 23 pneumococcal serotypes 30 days after vaccination

    Geometric mean fold increase (GMFI) of IgG antibodies against 23 pneumococcal serotypes 30 days after vaccination

    Time frame: 30 days

  2. GMC of 23 pneumococcal serotype IgG antibodies in the 3rd and 6th year after vaccination

    GMC of 23 pneumococcal serotype IgG antibodies in the 3rd and 6th year after vaccination

    Time frame: 3, 6 years after vaccination

Other outcomes

  1. The proportion of subjects with ≥0.35ug/mL IgG antibodies to 23 pneumococcal serotypes 30 days after vaccination,

    The proportion of subjects with ≥0.35ug/mL IgG antibodies to 23 pneumococcal serotypes 30 days after vaccination,

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • Sichuan Center For Disease Control and Prevention
    Chengdu, Sichuan, China
    Recruiting
    • Xuecheng LIU · Contact+8618981958206
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Mar 2024, 6 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 6 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2023
First posted
Sep 21, 2023
StartActual
Sep 8, 2023
Primary completionEst.
Mar 8, 2024
CompletionEst.
Jul 31, 2029
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06044077
Lead sponsor
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Sep 8, 2023
Primary completion
Mar 8, 2024 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Sep 21, 2023

Study contacts

Xuecheng LIU
Contact
534210793@qq.com
+86 189 8195 8206

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion